Clovis Oncology Inc (CLVS)

23.03
4.93 27.24
NASDAQ : Health Care
Prev Close 18.10
Open 18.30
Day Low/High 16.61 / 24.97
52 Wk Low/High 11.57 / 116.75
Volume 17.34M
Avg Volume 1.00M
Exchange NASDAQ
Shares Outstanding 38.50M
Market Cap 664.14M
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Oncology Announces Q2 2016 Operating Results And Corporate Update

Clovis Oncology Announces Q2 2016 Operating Results And Corporate Update

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Oncology To Announce Second Quarter 2016 Financial Results And Host Webcast Conference Call On August 8

Clovis Oncology To Announce Second Quarter 2016 Financial Results And Host Webcast Conference Call On August 8

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2016 financial results on Monday, August 8, 2016, after the close of the U.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Clovis Oncology Presents Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting

Clovis Oncology Presents Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting

Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in...

Clovis Oncology Announces Data Presentations At 2016 ASCO Annual Meeting

Clovis Oncology Announces Data Presentations At 2016 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced its presence at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated results from clinical studies of rucaparib.

Clovis Oncology Becomes Oversold (CLVS)

Clovis Oncology Becomes Oversold (CLVS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

The Shuman Law Firm Investigates Clovis Oncology, Inc.

The Shuman Law Firm Investigates Clovis Oncology, Inc.

The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Clovis Oncology, Inc.

Clovis Oncology Announces Q1 2016 Operating Results And Corporate Update

Clovis Oncology Announces Q1 2016 Operating Results And Corporate Update

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter ended March 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Oncology To Announce First Quarter 2016 Financial Results And Host Webcast Conference Call On May 5

Clovis Oncology To Announce First Quarter 2016 Financial Results And Host Webcast Conference Call On May 5

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.

Why Clovis Oncology (CLVS) Stock is Tumbling Today

Why Clovis Oncology (CLVS) Stock is Tumbling Today

Clovis Oncology (CLVS) stock is dipping on Wednesday as an FDA advisory committee voted against approving the company's lung cancer drug rociletinib yesterday.

Clovis Lung Cancer Drug Trashed at FDA Panel, CEO Exit Next?

Clovis Lung Cancer Drug Trashed at FDA Panel, CEO Exit Next?

An FDA advisory committee delivers a brutal beatdown of Clovis' lung cancer drug rociletinib. It could cost Clovis' CEO his job.

Trading Of Clovis Oncology, Inc. Common Stock Halted

Trading Of Clovis Oncology, Inc. Common Stock Halted

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company's common stock.

Why Clovis Oncology (CLVS) Stock is Dropping Today

Why Clovis Oncology (CLVS) Stock is Dropping Today

Clovis Oncology (CLVS) stock is continuing to slide on Monday after the FDA questioned its lung cancer drug Friday. An advisory panel is slated to vote on the drug tomorrow.

Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogether

Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogether

Clovis Oncology is better off if the U.S. Food and Drug Administration rejects its lung cancer drug rociletinib.

First Week of May 20th Options Trading For Clovis Oncology (CLVS)

First Week of May 20th Options Trading For Clovis Oncology (CLVS)

Investors in Clovis Oncology Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS options chain for the new May 20th contracts and identified one put and one call contract of particular interest.

Clovis Oncology Announces 2015 Operating Results

Clovis Oncology Announces 2015 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter and year ended December 31, 2015, and provided an update on the Company's clinical development programs and regulatory outlook for 2016.

Clovis Oncology To Announce Fourth Quarter/Year-End 2015 Financial Results And Host Webcast Conference Call On February 25

Clovis Oncology To Announce Fourth Quarter/Year-End 2015 Financial Results And Host Webcast Conference Call On February 25

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2015 financial results on Thursday, February 25, 2016, after the close of the U.

Clovis Oncology Initiates Immunotherapy Combination Trial

Clovis Oncology Initiates Immunotherapy Combination Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that it initiated a clinical trial to evaluate a novel combination therapy of Genentech's investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PD-L1) and...

Clovis Oncology Becomes Oversold (CLVS)

Clovis Oncology Becomes Oversold (CLVS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Clovis Oncology Appoints Dale Hooks As Chief Commercial Officer

Clovis Oncology Appoints Dale Hooks As Chief Commercial Officer

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Dale Hooks has been named Senior Vice President and Chief Commercial Officer.

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Clovis Oncology, Inc. Of Filing Of Class Action Lawsuit And Lead Plaintiff Deadline Of January 18, 2016 - CLVS

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Clovis Oncology, Inc. Of Filing Of Class Action Lawsuit And Lead Plaintiff Deadline Of January 18, 2016 - CLVS

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Clovis Oncology, Inc.

UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Clovis Oncology, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Clovis Oncology, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

INVESTOR ALERT: The Law Offices Of Vincent Wong Remind Investors Of Class Action Involving Clovis Oncology, Inc. And A Lead Plaintiff Deadline Of January 19, 2016

INVESTOR ALERT: The Law Offices Of Vincent Wong Remind Investors Of Class Action Involving Clovis Oncology, Inc. And A Lead Plaintiff Deadline Of January 19, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased Clovis Oncology, Inc.